METAglut1TM obtains universal national coverage by French National Health Insurance as of February 22, 2024 after approval by the French National Authority for Health.
A fine achievement for the collaborative work of several teams from l’AP-HP, l’IGMM Institut de Génétique Moléculaire de Montpellier (CNRS/Université de Montpellier) and Metafora-Biosystems .
METAglut1, a fast, reliable blood test, provides an early diagnosis of Glut1 deficiency syndrome, or De Vivo disease, a rare and disabling neurological condition.
